Curia Completes Upgrade of API Aseptic Suites in Valladolid, Spain
ALBANY, N.Y., May 19, 2026 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of
Curia Completes Upgrade of API Aseptic Suites in Valladolid, Spain
ALBANY, N.Y., May 19, 2026 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of
Curia Completes Upgrade of API Aseptic Suites in Valladolid, Spain
ALBANY, N.Y., May 19, 2026 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of
Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) — Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced
Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) — Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced
Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) — Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced